Interferons analysis

[Paul123456]

Interesting

ncbi.nlm.nih.gov/pmc/articl...

[Aneliv9]

I have read this before.. one of my questions is : can IFN work with triple negative patients?Or a mutation is necessary for inhibition through IFN?

[Paul123456 in reply to Aneliv9]

I’ve been trying to determine this but still don’t know for sure. My gut feeling us that it could/would. From what I have read, it appears you might want you ask for a full mutation panel test to see if there are any other mutations driving your MPN. Trials have shown that INFs can reduce some of these other mutations. I have TET2 which has halved after 12 months of Pegasys.

You should definitely ask your Hem about Pegasys

Best Paul

[Aneliv9 in reply to Paul123456]

You have exclusively the TET mutation ,or another one as well?

[Paul123456 in reply to Aneliv9]

TET2 + JAK2. Both were c. 80% March 2018, about 40% March 2019 after one year Pegasys

[Aneliv9 in reply to Paul123456]

I am triple negative ET. So scary in case i transform to triple negative MF. It is the worst of all. And i haven't clarify if there is going to be a future treatment for this subcategory

[Paul123456 in reply to Aneliv9]

When are you next seeing your Hem? And are they a MPN specialist?

If not or too long a wait until your next consultation, you could contact Maz, who is in charge of this Forum, to ask if she could kindly ask Prof Harrison re best treatment options for your condition

[Aneliv9 in reply to Paul123456]

Things are just like you said!! Very far away my next appointment and just asked Mazcd this exactly question. She replied that i must stay tuned till the 16th of November that somekind of meeting will take place in London about new drugs..

healthunlocked.com/mpnvoice...

[socrates_8]

It is as you say quite an interesting claim on many levels, however, they do have a ulterior according to the 'Conflicts of Interest' stated below over 'Patents'.

Still these are very broad-reaching claims. There is no mention here at all of side-effects to or by any patients either... ?

Interesting Paul, all the same...

Steve

[Marossi]

Thanks for posting Paul. Lots of food for thought.

[mhos61]

Thanks Paul,

I only got to page 25. A bit of brain fog now setting in. It is very interesting, I didn’t know the percentage was so high (40%) for secondary cancers in the MPN population.

I will definitely read the remainder tomorrow.

[Aneliv9 in reply to mhos61]

It not as high as it sounds. Google for relative risk and absolute risk. I am almost sure that 40% is a relative risk, a risk in comparison with another healthy group

[Paul123456]

Aneliv9

If you have not seen this, worth reading. It’s 2018 so not too old

ncbi.nlm.nih.gov/pmc/articl...

[Dolman]

Interesting Paul , do you know if any of these treatments can be used on jak2 negative patients as everything I seem to read targets the jak2 which I am negative but have been told I still have Pv .

[Paul123456]

Ruxo targets JAK2 but Interferons are much more root cause. Hence achieve a lot more than just reduce JAK. Has also reduced TET2 in my case. Plus, the exciting bit is whether it can actually impact disease progression. From reading other Forums there are certainly some people who claim fairly impressive results.

As a generalisation, HU supporters claim good haematological results, Ruxo users are grateful for life transforming reductions in symptom burden but only those successfully using Pegasys/Interferons are delighted their drug of choice and think, rightly or wrongly, that they are slowing progression

FWIW I repeat my previous pet theory re inflammation. I’m absolutely convinced that reducing inflammation (via diet, supplements, herbs etc and exercise) makes a massive difference to reducing symptom burden and, if on Pegasys, my guess is will significantly improve its effectiveness .